ImmuneXcite will be exploring a limited number of strategic partnerships to more fully leverage its technology and programs. In particular, our mAbXcite technology offers compelling advantages for potential partners that have novel tumor targeting antibodies with high tumor specificity, regardless of the antibodies’ biological activity.

In 2015, ImmuneXcite established undisclosed early-stage collaborations with two of the leading biopharmaceutical companies in the immuno-oncology space.

If you are interested in learning more about ImmuneXcite’s technology and programs, or discussing potential partnering opportunities, please contact John Edwards at